Gossamer Bio, Inc. announced the appointment of John Quisel, J.D., Ph.D., President and CEO of Disc Medicine, to its Board of Directors. Dr. Quisel is currently the President and CEO of Disc Medicine, a position he has held since January 2020 and during which time, the company established a multi-product portfolio of hematology programs and became a publicly-traded company. Previously, Dr. Quisel was the Executive Vice President and Chief Business Officer at Acceleron Pharma, where he spent more than thirteen years in various senior roles helping to build the company from a privately-held startup to a fully-integrated, publicly-traded company.

Dr. Quisel led the initiative to re-acquire rights for sotatercept for pulmonary hypertension from Bristol-Myers Squibb, which eventually led to the acquisition of Acceleron by Merck & Co. for over $11 billion in 2021. During his tenure, Dr. Quisel also served in various roles, including Senior Vice President of Corporate Development and General Counsel.

Prior to Acceleron, he was an attorney at the firms Ropes & Gray and Foley Hoag. Dr. Quisel received an A.B. in biological sciences from Harvard College, an M.Sc. in biology from Stanford University, a Ph.D. in biology from the Massachusetts Institute of Technology, and a J.D. from Harvard Law School.

The Board appointed John Quisel, J.D., Ph.D. to serve as a Class III director, with an initial term expiring at the Company?s 2024 annual meeting of stockholders. In connection with Dr. Quisel?s appointment, the Board has appointed Dr. Quisel to the Audit Committee of the Board (the "Audit Committee").